These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27885753)

  • 21. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.
    Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2016 Jun; 23(6):408-18. PubMed ID: 27018088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
    Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
    Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.
    Di Martino V; Crouzet J; Hillon P; Thévenot T; Minello A; Monnet E
    J Viral Hepat; 2011 Jul; 18(7):493-505. PubMed ID: 21692956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis.
    García-García JA; Romero-Gómez M; Girón-González JA; Rivera-Irigoin R; Torre-Cisneros J; Montero JL; González-Serrano M; Andrade RJ; Aguilar-Guisado M; Grilo I; Martín-Vivaldi J; Salmerón J; Caballero-Granado FJ; Macías J; Vergara-López S; Pineda JA; ;
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1236-41. PubMed ID: 17209765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments.
    Mar J; Martínez-Baz I; Ibarrondo O; Juanbeltz R; San Miguel R; Casado I; O'Leary A; Castilla J
    Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):699-708. PubMed ID: 28946785
    [No Abstract]   [Full Text] [Related]  

  • 27. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
    PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
    Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
    J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
    Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
    Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.
    Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ
    JHEP Rep; 2022 Oct; 4(10):100552. PubMed ID: 36119722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.
    Sangiovanni A; Prati GM; Fasani P; Ronchi G; Romeo R; Manini M; Del Ninno E; Morabito A; Colombo M
    Hepatology; 2006 Jun; 43(6):1303-10. PubMed ID: 16729298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history of hepatitis C.
    Westbrook RH; Dusheiko G
    J Hepatol; 2014 Nov; 61(1 Suppl):S58-68. PubMed ID: 25443346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients.
    Solà R; Alvarez MA; Ballesté B; Montoliu S; Rivera M; Miquel M; Cirera I; Morillas RM; Coll S; Planas R
    Liver Int; 2006 Feb; 26(1):62-72. PubMed ID: 16420511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan.
    McDonald SA; Hutchinson SJ; Innes HA; Allen S; Bramley P; Bhattacharyya D; Carman W; Dillon JF; Fox R; Fraser A; Goldberg DJ; Kennedy N; Mills PR; Morris J; Stanley AJ; Wilks D; Hayes PC
    J Viral Hepat; 2014 May; 21(5):366-76. PubMed ID: 24716639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Projecting future complications of chronic hepatitis C in the United States.
    Davis GL; Albright JE; Cook SF; Rosenberg DM
    Liver Transpl; 2003 Apr; 9(4):331-8. PubMed ID: 12682882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.